This report examines the savings generated by increasing access to a new medication category—proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i)—which effectively manages dyslipidemia (high cholesterol) in two populations at high risk for cardiovascular disease.
Reducing Cardiovascular Disease in Canada: The Impact of PCSK9 Inhibitors in High-Risk Populations
Reducing Cardiovascular Disease in Canada: The Impact of PCSK9 Inhibitors in High-Risk Populations
Health and Healthcare
$0.00
Cardiovascular disease (CVD) prevalence incurs significant costs to governments and society in the form of hospitalizations, disease management, and lost productivity. Also, some individuals are at increased risk of a first or repeat CVD event due to high LDL cholesterol (LDL-C) levels. This report investigates the impact of increasing access to a new medication category—proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i)—which effectively manages dyslipidemia (high cholesterol) in two high-risk populations.
Discover why PCSK9i, recommended by Canadian guidelines for the treatment of dyslipidemia in high-risk patients, can lead to billions of dollars in direct cost savings to the Canadian health care system and indirect cost savings from lost productivity due to premature mortality and hospitalizations.
Customers Who Downloaded This Also Liked
Require an accessible version of this research?
Upon request, Signal49 Research offers accessible versions of research. Please contact us to request your accessible version.
Learn more about our accessibility policies.
Effective January 26, 2026, AERIC Inc./Signal49 Research discontinued use of ‘The Conference Board of Canada’ name, logo and branding, which had been used by AERIC Inc./Signal49 Research under license from The Conference Board, Inc. The Conference Board, Inc. and its licensees, which are not affiliated with Signal49 Research, own all right, title and interest in THE CONFERENCE BOARD name and trademarks in Canada and have the exclusive right to their use in Canada since January 26, 2026.
